Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

animal health

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

- PMLiVE

Sanofi and Boehringer Ingelheim complete €21.8bn asset swap

Exchange of animal health and consumer interests sharpens the firm's focus

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

Sanofi reception

Lilly and Boehringer launch first Lantus clone Basaglar in US

Starts biosimilar at 15% discount to Sanofi’s basal insulin product

- PMLiVE

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

- PMLiVE

CHMP recommends Merck & Co’s Lantus biosimilar

Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo

Deal Watch October 2016

Allergan, Astellas, AstraZeneca, Boehringer Ingelheim and Eli Lilly feature in this month's pharma deals round-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links